Tumor Biology

, Volume 37, Issue 2, pp 2519–2526 | Cite as

Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells

  • Ingun Heiene Tveteraas
  • Monica Aasrum
  • Ingvild Johnsen Brusevold
  • John Ødegård
  • Thoralf Christoffersen
  • Dagny Sandnes
Original Article

Abstract

Lysophosphatidic acid (LPA) is a small glycerophospholipid ubiquitously present in tissues and plasma. It acts through receptors belonging to the G-protein-coupled receptor (GPCR) family, is involved in several biological processes, and is strongly implicated in different cancers. In this paper, we have investigated the effects of LPA on DNA synthesis and migration in a panel of pancreatic and colon cancer cells, with particular focus on the involvement of the epidermal growth factor (EGF) receptor (EGFR) in LPA-induced signaling. LPA stimulated DNA synthesis and/or migration in all the cell lines included in this study. In five of the six cell lines, LPA induced phosphorylation of the EGFR, and the effects on EGFR and Akt, and in some of the cells also ERK, were sensitive to the EGFR tyrosine kinase inhibitor gefitinib, strongly suggesting LPA-induced EGFR transactivation in these cells. In contrast, in one of the pancreatic carcinoma cell lines (Panc-1), we found no evidence of transactivation of the EGFR. In the pancreatic carcinoma cell lines where transactivation took place (BxPC3, AsPC1, HPAFII), gefitinib reduced LPA-induced DNA synthesis and/or migration. However, we also found evidence of transactivation in the two colon carcinoma cell lines (HT29, HCT116) although gefitinib did not inhibit LPA-induced DNA synthesis or migration in these cells. Taken together, the data indicate that in many gastrointestinal carcinoma cells, LPA uses EGFR transactivation as a mechanism when exerting such effects as stimulation of cell proliferation and migration, but EGFR-independent pathways may be involved instead of, or in concerted action with, the EGFR transactivation.

Keywords

EGFR transactivation Lysophosphatidic acid (LPA) Colon cancer Pancreatic cancer 

References

  1. 1.
    Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011;30:557–65.CrossRefPubMedGoogle Scholar
  2. 2.
    Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 2010;92:698–706.CrossRefPubMedGoogle Scholar
  3. 3.
    Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157–86.CrossRefPubMedGoogle Scholar
  4. 4.
    Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Stortelers C, Kerkhoven R, Moolenaar WH. Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics. 2008;9:387.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004;279:20555–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ishii S, Noguchi K, Yanagida K. Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat. 2009;89:57–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Gotoh M, Fujiwara Y, Yue J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans. 2012;40:31–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Radhika V, Hee Ha J, Jayaraman M, et al. Mitogenic signaling by lysophosphatidic acid (LPA) involves Galpha12. Oncogene. 2005;24:4597–603.CrossRefPubMedGoogle Scholar
  10. 10.
    Shida D, Fang X, Kordula T, et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008;68:6569–77.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Panupinthu N, Yu S, Zhang D, et al. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 2014;33:2846–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Cai H, Xu Y. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal. 2013;11:31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hwang YS, Lee SK, Park KK, et al. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. Oral Oncol. 2012;48:40–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim JH, Adelstein RS. LPA(1)-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol. 2011;226:2881–93.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lee SJ, Yun CC. Colorectal cancer cells - Proliferation, survival and invasion by lysophosphatidic acid. Int J Biochem Cell Biol. 2010;42:1907–10.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Park SY, Jeong KJ, Panupinthu N, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 2011;30:1351–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Schulte KM, Beyer A, Kohrer K, et al. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer. 2001;92:249–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest. 2004;84:1352–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Sokolov E, Eheim AL, Ahrens WA, et al. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma. J Surg Res. 2013;180:104–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008;100:1630–42.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med. 2007;9:1–18.CrossRefPubMedGoogle Scholar
  22. 22.
    Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–214.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21:177–84.CrossRefPubMedGoogle Scholar
  25. 25.
    Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Fischer OM, Hart S, Gschwind A, et al. EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003;31:1203–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Fischer OM, Hart S, Ullrich A. Dissecting the epidermal growth factor receptor signal transactivation pathway. Methods Mol Biol. 2006;327:85–97.PubMedGoogle Scholar
  30. 30.
    George AJ, Hannan RD, Thomas WG. Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J. 2013;280:5258–68.CrossRefPubMedGoogle Scholar
  31. 31.
    Gschwind A, Zwick E, Prenzel N, et al. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene. 2001;20:1594–600.CrossRefPubMedGoogle Scholar
  32. 32.
    Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol. 2011;331:222–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213:589–602.CrossRefPubMedGoogle Scholar
  34. 34.
    Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 2002;62:6329–36.PubMedGoogle Scholar
  35. 35.
    Mori K, Kitayama J, Shida D, et al. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res. 2006;132:56–61.CrossRefPubMedGoogle Scholar
  36. 36.
    Dajani OF, Meisdalen K, Guren TK, et al. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J Cell Physiol. 2008;214:371–80.CrossRefPubMedGoogle Scholar
  37. 37.
    Tveteraas IH, Muller KM, Aasrum M, et al. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res. 2012;31:72.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Holmstrom TE, Mattsson CL, Wang Y, et al. Non-transactivational, dual pathways for LPA-induced Erk1/2 activation in primary cultures of brown pre-adipocytes. Exp Cell Res. 2010;316:2664–75.CrossRefPubMedGoogle Scholar
  39. 39.
    Brusevold IJ, Tveteraas IH, Aasrum M, et al. Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells. BMC Cancer. 2014;14:432.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Loukopoulos P, Kanetaka K, Takamura M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193–203.CrossRefPubMedGoogle Scholar
  41. 41.
    Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425–35.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Refsnes M, Thoresen GH, Dajani OF, et al. Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor. J Cell Physiol. 1994;159:35–40.CrossRefPubMedGoogle Scholar
  43. 43.
    Brusevold IJ, Aasrum M, Bryne M, et al. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med. 2012;41:547–58.PubMedGoogle Scholar
  44. 44.
    Komachi M, Tomura H, Malchinkhuu E, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30:457–65.CrossRefPubMedGoogle Scholar
  45. 45.
    Stahle M, Veit C, Bachfischer U, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci. 2003;116:3835–46.CrossRefPubMedGoogle Scholar
  46. 46.
    Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595–605.CrossRefPubMedGoogle Scholar
  47. 47.
    Muller KM, Tveteraas IH, Aasrum M, et al. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer. 2011;11:421.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Oyesanya RA, Greenbaum S, Dang D, et al. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Mol Cancer. 2010;9:8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Rubio I, Rennert K, Wittig U, et al. Ras activation in response to lysophosphatidic acid requires a permissive input from the epidermal growth factor receptor. Biochem J. 2003;376:571–6.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Leserer M, Gschwind A, Ullrich A. Epidermal growth factor receptor signal transactivation. IUBMB Life. 2000;49:405–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Gardner JA, Ha JH, Jayaraman M, et al. The gep proto-oncogene Galpha13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells. Pancreas. 2013;42:819–28.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Leve F, Marcondes TG, Bastos LG, et al. Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells. Eur J Pharmacol. 2011;671:7–17.CrossRefPubMedGoogle Scholar
  53. 53.
    Sun H, Ren J, Zhu Q, et al. Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World J Gastroenterol. 2009;15:4547–55.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ingun Heiene Tveteraas
    • 1
  • Monica Aasrum
    • 1
  • Ingvild Johnsen Brusevold
    • 1
    • 2
  • John Ødegård
    • 1
  • Thoralf Christoffersen
    • 1
  • Dagny Sandnes
    • 1
  1. 1.Department of Pharmacology, Institute of Clinical Medicine, Faculty of MedicineUniversity of Oslo and Oslo University HospitalBlindernNorway
  2. 2.Department of Oral Biology and Department of Paediatric Dentistry and Behavioural Science, Faculty of DentistryUniversity of OsloBlindernNorway

Personalised recommendations